Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial

Park, Youngjae; Lee, Yoon Jae; Koh, Jung Hee; Lee, Jennifer; Min, Hong Ki; Kim, Moon Young; Kim, Ki Joo; Lee, Su Jin; Rhie, Jong Won; Kim, Wan‐Uk; Park, Sung-Hwan; Moon, Suk‐Ho; Kwok, Seung‐Ki

doi:10.3390/jcm9093023

Cited by 21 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in one of the cases cells were co-injected with PRP ( Virzì et al, 2017 ). None adverse events were observed, except in two cases where transient paresthesia, pains or pallor in hands were observed ( Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ; Park Y. et al, 2020 ). Considering effectiveness, those studies with published results demonstrated the benefits of this methodology: Granel et al and Guillaume-Jugnot et al compared the evolution of the disease from the baseline to 12 months after treatment, reporting a significant improvement of 46.8% for the Scleroderma Health Assessment Questionnaire, of 51.3% for the Cochin Hand Function Scale (CHFS) score and of 63.2% for the Raynaud’s Condition score ( Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ).…”

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 92%

“…Ten clinical studies have reported the use of hMSCs as advanced therapy for the treatment of systemic sclerosis in the last 5 years ( Table 9 ; Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ; Wehbe et al, 2016 ; Song et al, 2017 ; Virzì et al, 2017 ; Zhang et al, 2017 ; Van Rhijn-Brouwer et al, 2018 ; Park Y. et al, 2020 ) (NCT02975960 and NCT04356287). Among these studies, three studies were case reports ( Wehbe et al, 2016 ; Song et al, 2017 ; Virzì et al, 2017 ), in contrast to the rest which were clinical trials.…”

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

“…Human MSCs used as CT were isolated from adipose tissue (hAT-MSCs) ( Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ; Song et al, 2017 ; Virzì et al, 2017 ; Park Y. et al, 2020 ) (NCT02975960), umbilical cord blood (hUCB-MSCs) ( Wehbe et al, 2016 ; Zhang et al, 2017 ) (NCT04356287), and bone marrow (hBM-MSCs) ( Van Rhijn-Brouwer et al, 2018 ). Interestingly, in all cases where hAT-MSCs were used, autologous source was preferred.…”

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

“…Among those studies which applied autologous hAT-MSCs ( n = 44), the number of cells injected varied from 3.76 ± 1.85 (1.19–7.07) × 10 6 ( Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ), 2.72 × 10 6 cells ( Song et al, 2017 ) to 3.61 ± 4.34 × 10 6 ( Park Y. et al, 2020 ). Interestingly, in one of the cases cells were co-injected with PRP ( Virzì et al, 2017 ).…”

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

“…Considering effectiveness, those studies with published results demonstrated the benefits of this methodology: Granel et al and Guillaume-Jugnot et al compared the evolution of the disease from the baseline to 12 months after treatment, reporting a significant improvement of 46.8% for the Scleroderma Health Assessment Questionnaire, of 51.3% for the Cochin Hand Function Scale (CHFS) score and of 63.2% for the Raynaud’s Condition score ( Granel et al, 2015 ; Guillaume-Jugnot et al, 2015 ). Virzì et al (2017) observed that co-injection of PRP and hAT-MSCs increased skin elasticity in perioral and malar areas (16.64% for the lip and the 17.80% for the cheek) ( Virzì et al, 2017 ); and Park Y. et al (2020) reported a slight improvement of Raynaud’s Condition Scale value but without significance (from 5 to 6), although health assessment questionnaire reported better values after 24 weeks (from 1.0 to 0.625) and better quality of life was observed.…”

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

See 4 more Smart Citations

Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Sierra-Sánchez

Montero‐Vílchez

Quiñones-Vico

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Skin disease may be related with immunological disorders, external aggressions, or genetic conditions. Injuries or cutaneous diseases such as wounds, burns, psoriasis, and scleroderma among others are common pathologies in dermatology, and in some cases, conventional treatments are ineffective. In recent years, advanced therapies using human mesenchymal stem cells (hMSCs) from different sources has emerged as a promising strategy for the treatment of many pathologies. Due to their properties; regenerative, immunomodulatory and differentiation capacities, they could be applied for the treatment of cutaneous diseases. In this review, a total of thirteen types of hMSCs used as advanced therapy have been analyzed, considering the last 5 years (2015–2020). The most investigated types were those isolated from umbilical cord blood (hUCB-MSCs), adipose tissue (hAT-MSCs) and bone marrow (hBM-MSCs). The most studied diseases were wounds and ulcers, burns and psoriasis. At preclinical level, in vivo studies with mice and rats were the main animal models used, and a wide range of types of hMSCs were used. Clinical studies analyzed revealed that cell therapy by intravenous administration was the advanced therapy preferred except in the case of wounds and burns where tissue engineering was also reported. Although in most of the clinical trials reviewed results have not been posted yet, safety was high and only local slight adverse events (mild nausea or abdominal pain) were reported. In terms of effectiveness, it was difficult to compare the results due to the different doses administered and variables measured, but in general, percentage of wound’s size reduction was higher than 80% in wounds, Psoriasis Area and Severity Index and Severity Scoring for Atopic Dermatitis were significantly reduced, for scleroderma, parameters such as Modified Rodnan skin score (MRSC) or European Scleroderma Study Group activity index reported an improvement of the disease and for hypertrophic scars, Vancouver Scar Scale (VSS) score was decreased after applying these therapies. On balance, hMSCs used for the treatment of cutaneous diseases is a promising strategy, however, the different experimental designs and endpoints stablished in each study, makes necessary more research to find the best way to treat each patient and disease.

show abstract

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 92%

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

Section: Mesenchymal Stem Cells In Cutaneous Injuries or Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Sierra-Sánchez

Montero‐Vílchez

Quiñones-Vico

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Evaluating the effects of digital stromal vascular fraction injections in systemic sclerosis patients: a retrospective study

Nietlispach,

Besmens,

Jordan

et al. 2024

Eur J Plast Surg

View full text Add to dashboard Cite

Objective Managing hand symptoms in patients with systemic sclerosis is difficult, and the current treatments often provide only limited relief of. In 2014 a new treatment for theses patients was proposed for improving hand function, namely the digital injection of adipose tissue derived stem cells. Methods From 2015 to 2017 seven systemic sclerosis patients with an impaired hand function were treated with the aforesaid injections. A medical chart review was performed to collect pre- and postoperative patient specific data. Results Our findings indicated no significant improvement in nailfold capillaroscopic measurements or in the healing of preexisting digital ulcers. Additionally, patients reported a slight worsening in hand function after the treatment. However, we observed a decrease in the modified Rodnan skin score, which measures skin thickness Although previous research has verified the safety and feasibility of this treatment, we found no definitive evidence of its effectiveness. Conclusion Our results suggest that the specific conditions under which this treatment could be beneficial need to be identified through randomized controlled trials involving larger groups of patients. Level of Evidence: Level IV, therapeuticstudy.

show abstract

Revolutionizing dermatology: harnessing mesenchymal stem/stromal cells and exosomes in 3D platform for skin regeneration

Bicer

2024

Arch Dermatol Res

View full text Add to dashboard Cite

Contemporary trends reveal an escalating interest in regenerative medicine-based interventions for addressing refractory skin defects. Conventional wound healing treatments, characterized by high costs and limited efficacy, necessitate a more efficient therapeutic paradigm to alleviate the economic and psychological burdens associated with chronic wounds. Mesenchymal stem/stromal cells (MSCs) constitute cell-based therapies, whereas cell-free approaches predominantly involve the utilization of MSC-derived extracellular vesicles or exosomes, both purportedly safe and effective. Exploiting the impact of MSCs by paracrine signaling, exosomes have emerged as a novel avenue capable of positively impacting wound healing and skin regeneration. MSC-exosomes confer several advantages, including the facilitation of angiogenesis, augmentation of cell proliferation, elevation of collagen production, and enhancement of tissue regenerative capacity. Despite these merits, challenges persist in clinical applications due to issues such as poor targeting and facile removal of MSC-derived exosomes from skin wounds. Addressing these concerns, a three-dimensional (3D) platform has been implemented to emend exosomes, allowing for elevated levels, and constructing more stable granules possessing distinct therapeutic capabilities. Incorporating biomaterials to encapsulate MSC-exosomes emerges as a favorable approach, concentrating doses, achieving intended therapeutic effectiveness, and ensuring continual release. While the therapeutic potential of MSC-exosomes in skin repair is broadly recognized, their application with 3D biomaterial scenarios remains underexplored. This review synthesizes the therapeutic purposes of MSCs and exosomes in 3D for the skin restoration, underscoring their promising role in diverse dermatological conditions. Further research may establish MSCs and their exosomes in 3D as a viable therapeutic option for various skin conditions.

show abstract

Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial

Cited by 21 publications

References 28 publications

Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Evaluating the effects of digital stromal vascular fraction injections in systemic sclerosis patients: a retrospective study

Revolutionizing dermatology: harnessing mesenchymal stem/stromal cells and exosomes in 3D platform for skin regeneration

Contact Info

Product

Resources

About